Toronto, Ontario – TheNewswire - 5 September 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announced today that it has elected not to proceed with the previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (together, “GEM”). The Company entered into a non-binding term sheet dated O ...

Core Viewpoint - Helix BioPharma Corp. has successfully closed a non-brokered private placement of 2,222,333 common shares at a price of $0.75 per share, raising gross proceeds of $1,666,750, as part of its bridge financing strategy to secure larger institutional investments [1][2]. Group 1: Private Placement Details - The recent private placement follows a previous one of $3,000,000 announced on January 9, 2025, marking the second phase in Helix's financing strategy [2]. - The net proceeds from this private placement will be allocated towards near-term development activities and working capital [2]. - The offering is subject to final approval from the Toronto Stock Exchange, with a hold period of four months and one day expiring on December 23, 2025 [2]. Group 2: Company Overview - Helix BioPharma is focused on developing innovative solutions for hard-to-treat cancers, with its pipeline led by Tumor Defense Breaker™ L-DOS47, which is designed to enhance the effectiveness of existing cancer therapies [5]. - L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its foundation with Helix's next-generation bi-specific antibody-drug conjugates currently in discovery [5]. - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug [5].

Core Insights - Helix BioPharma Corp. announced the publication of a peer-reviewed article on the safety of L-DOS47, an unconventional antibody-drug conjugate, in treating advanced non-small cell lung cancer (NSCLC) [1][2] Company Overview - Helix BioPharma is a clinical-stage oncology company focused on developing innovative treatments for hard-to-treat cancers, with L-DOS47 as its lead candidate [4] - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug [5] Clinical Study Findings - The Phase I/II study of L-DOS47 demonstrated good tolerability at doses up to 13.55 µg/kg, with a median progression-free survival (PFS) of 4.1 months in the highest dosing quartile [3] - No complete or partial responses were observed, but higher doses correlated with a statistically significant extension in PFS (P=0.0203) [3] - CEACAM6 was found to be highly expressed in nearly half of NSCLC cases, suggesting its potential as a biomarker for patient selection in future trials [3] Future Development Plans - Helix plans to advance L-DOS47 into a new clinical study in combination with the PD-1 inhibitor pembrolizumab, aiming to enhance the efficacy of immunotherapies by neutralizing tumor acidity [3] - The company has received positive feedback from the FDA regarding the planned Phase I/II study in combination with pembrolizumab [3]